IDXGINTERPACE BIOSCIENCES, INC.
- GlobeNewswire
Interpace Biosciences Announces Second Quarter 2026 Financial and Business Results
Q2 Revenue of $9.1 millionQ2 Income from Continuing Operations of $0.3 millionQ2 Thyroid volume year-over-year increase of 6%Q2 Thyroid revenue year-over-year increase of 9%Trailing twelve-month thyroid revenue of $36.1 ...
- GlobeNewswire
Interpace Biosciences Announces First Quarter 2026 Financial and Business Results
Q1 Revenue of $9.0 millionQ1 Income from Continuing Operations of $0.8 millionQ1 Thyroid volume year-over-year increase of 10%Q1 Thyroid revenue year-over-year increase of 12% PARSIPPANY, NJ, May 12, 2026 (GLOBE ...
- GlobeNewswire
Interpace Biosciences Announces Fourth Quarter and Full Year 2025 Financial and Business Results
Q4 and FY Revenue of $9.2 million and $38.7 millionQ4 and FY Income from Continuing Operations of $22.8 million and $25.0 million (benefiting from a one-time, non-cash tax-related accounting adjustment)Q4 and FY Thyroid ...
- GlobeNewswire
Interpace Biosciences Announces Third Quarter 2025 Financial and Business Results
●Q3 Revenue of $8.8 million ●Q3 Cash Collections of $10.0 million ●Q3 Thyroid test volume up 12% year-over-year to record levels ●Q3 Thyroid revenue of $8.8M; up 22% year-over-year to record levels PARSIPPANY, NJ, ...
- GlobeNewswire
Interpace Biosciences Presented Two New Posters at the 2025 American Thyroid Association® (ATA) Annual Meeting
Highlights Independent institutional experience shows archival cytology slides enabled successful molecular results in cases previously insufficient for testing by another commercially available molecular diagnostic ...
- SEC
8-K Form - Current report, items 2.02 and 9.01 - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
Current report, items 2.02 and 9.01 ...
- SEC
10-Q Form - Quarterly report [Sections 13 or 15(d)] - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
Quarterly report [Sections 13 or 15(d)] ...
- GlobeNewswire
Interpace Biosciences Announces Second Quarter 2025 Financial and Business Results
●Q2 Revenue of $9.2 million ●Q2 Cash Collections of $10.8 million ●Q2 Thyroid test volume up 16% year-over-year to record levels ●Q2 Thyroid revenue of $8.7M; up 25% year-over-year to record levels PARSIPPANY, NJ, Aug. ...
- SEC
10-Q Form - Quarterly report [Sections 13 or 15(d)] - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
Quarterly report [Sections 13 or 15(d)] ...
- SEC
8-K Form - Current report, items 2.02 and 9.01 - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
Current report, items 2.02 and 9.01 ...
- GlobeNewswire
Interpace Biosciences Announces First Quarter 2025 Financial and Business Results
●Q1 Revenue of $11.5 million; a 13% increase year-over-year ●Q1 Cash Collections of $11.3 million; a 10% increase year-over-year to record levels ●Q1 Thyroid test volume up 16% year-over-year to record levels ●Q1 ...
- SEC
8-K Form - Current report, items 2.05, 8.01, and 9.01 - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
Current report, items 2.05, 8.01, and 9.01 ...
- SEC
10-K/A Form - [Amend] Annual report [Section 13 and 15(d), not S-K Item 405] - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
[Amend] Annual report [Section 13 and 15(d), not S-K Item 405] ...
- SEC
4 Form - Statement of changes in beneficial ownership of securities - INTERPACE BIOSCIENCES, INC. (0001054102) (Issuer)
Statement of changes in beneficial ownership of securities ...
- GlobeNewswire
Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk
Interpace Expects to Remain Profitable as a Thyroid-focused Business PARSIPPANY, NJ, April 24, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, ("Interpace" or the ...
- SEC
10-K Form - Annual report [Section 13 and 15(d), not S-K Item 405] - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
Annual report [Section 13 and 15(d), not S-K Item 405] ...
- SEC
8-K Form - Current report, item 4.02 - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
Current report, item 4.02 ...
- SEC
SCHEDULE 13G/A Form - [Amend] Statement of Beneficial Ownership by Certain Investors - INTERPACE BIOSCIENCES, INC. (0001054102) (Subject)
[Amend] Statement of Beneficial Ownership by Certain Investors ...
- SEC
SCHEDULE 13G/A Form - [Amend] Statement of Beneficial Ownership by Certain Investors - INTERPACE BIOSCIENCES, INC. (0001054102) (Subject)
[Amend] Statement of Beneficial Ownership by Certain Investors ...
- GlobeNewswire
Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2024 Financial and Business Results
●Q4 and FY Test volume increase 21% and 17% year-over-year ●Q4 and FY Volume, Revenue, and Profitability at all-time record levels PARSIPPANY, NJ, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ...
- GlobeNewswire
PancraGEN® Will Continue to be Offered While Interpace Re-evaluates its Previously Announced Re-structuring Plan
PARSIPPANY, NJ, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, ("Interpace" or the "Company") (OTCQX:IDXG) today announced notification that the Centers for ...
- GlobeNewswire
Effective 02/07/2025, Interpace Diagnostics® to No Longer Offer PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk
PARSIPPANY, NJ, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, ("Interpace" or the "Company") (OTCQX:IDXG) today responded to the final Local Coverage ...
- SEC
8-K Form - Current report, item 5.07 - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
Current report, item 5.07 ...
- SEC
10-Q Form - Quarterly report [Sections 13 or 15(d)] - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
Quarterly report [Sections 13 or 15(d)] ...
- GlobeNewswire
Interpace Biosciences Announces Record Third Quarter 2024 Financial and Business Results
●Q3 Revenue of $12.3 million; a $3.2M and 35% increase year-over-year ●Q3 Test volume up 26% year over year to record levels ●Q3 Cash collections of $11.3M; a $1.4M and 15% increase year-over-year ●Q3 Volume, Revenue, ...